Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
130
datasets available to search
ShareScore release 0.9.0
Dataset results
130 results for “Shigella”
Multidrug Resistant Shigella Infection in Bangladesh
ClinicalTrials.gov study NCT03778125. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
ClinicalTrials.gov study NCT02388009. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.
ClinicalTrials.gov study NCT06523231. IPD Sharing: NO. Countries: 1. Publications: 17.
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
ClinicalTrials.gov study NCT01369927. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
ClinicalTrials.gov study NCT01531530. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
ClinicalTrials.gov study NCT04056117. IPD Sharing: NO. Countries: 1. Publications: 12.
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
ClinicalTrials.gov study NCT04312906. IPD Sharing: UNDECIDED. Countries: 2. Publications: 4.
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
ClinicalTrials.gov study NCT02034500. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
ClinicalTrials.gov study NCT06615375. IPD Sharing: NO. Countries: 1. Publications: 14.
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
ClinicalTrials.gov study NCT01069471. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A tale of two plasmids: contributions of plasmid associated phenotypes to epidemiological success among Shigella
Open the record for dataset details and reuse information.
Selection for phage resistance reduces virulence of Shigella flexneri
<p>There is increasing interest in phage therapy as an alternative to chemical antibiotics for treating bacterial infections, especially using phages that select for evolutionary trade-offs between increased phage resistance and decreased fitness traits such as virulence in target bacteria. A vast repertoire of virulence factors allows the opportunistic bacterial pathogen, <i>Shigella flexneri</i>, to invade human gut epithelial cells, to replicate intracellularly, and to evade host immunity through intercellular spread; the latter is an infection stage that causes tissue damage, contributing to host mortality. It is previously shown that outer membrane porin OmpA of <i>S. flexneri</i> is necessary for polar localization of virulence factor IcsA, which polymerizes host actin and results in bacterial motility within infected cells. We hypothesized that a phage which uses OmpA as a receptor to recognize, bind and infect <i>S. flexneri</i>, should select for phage-resistant mutants with attenuated intercellular spread. Here we show that a naturally-isolated <i>Myoviridae</i> virus, phage A1-1, requires OmpA as a receptor, and selects for reduced virulence in <i>S. flexneri</i>. We characterized five phage-resistant mutants by measuring their phenotypic changes relative to wildtype bacteria in various traits: cell-membrane permeability, total lipopolysaccharide (LPS), sensitivity to four antibiotics, and susceptibility to infection by phages T7 and 60B. Results separated the mutants into two groups: R1 and R2 phenotypically resembled <i>ompA</i> knockouts, whereas R3, R4 and R5 were similar to LPS-deficient strains. Whole genome sequencing confirmed that R1 and R2 had mutations in <i>ompA</i>, while R3, R4 and R5 showed mutations in LPS inner-core biosynthesis genes <i>gmhA</i> and <i>gmhC</i>. Bacterial plaque assays in Vero cells confirmed that all five phage-resistant mutants were incapable of intercellular spread. We concluded that selection for <i>S. flexneri</i> resistance to phage A1-1 generally reduced the virulence trait intercellular spread, but this trade-off could be mediated either by mutations in <i>ompA</i> or those in LPS-core genes that likely altered OmpA conformation.</p>
The Supplementary tables of manuscript "Low Reproductive of Giant Pandas May Be Associated with Increased Vaginal Escherichia-Shigella"
Open the record for dataset details and reuse information.
FIGURE 134 in Structural characterization of the type III pilotin-secretin interaction in Shigella flexneri by NMR spectroscopy
FIGURE 134. Labelled diagram of the female genitalia of the Australian nacophorine Paralaea jarrah.
A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a
ClinicalTrials.gov study NCT04602975. IPD Sharing: NO. Countries: 1. Publications: 0.
Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
ClinicalTrials.gov study NCT04078022. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Shigella Sonnei OSPC-rDT Conjugate Vaccine
ClinicalTrials.gov study NCT01399424. IPD Sharing: Not stated. Countries: 0. Publications: 3.
A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
ClinicalTrials.gov study NCT02676895. IPD Sharing: YES. Countries: 1. Publications: 0.
Shigella WRSS1 Vaccine Trial in Bangladesh
ClinicalTrials.gov study NCT02934178. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
ClinicalTrials.gov study NCT04634513. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.